FindTrial
Sign In

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512501-76-00
Acronym
EFC15467
Enrollment
3
Registered
2024-06-04
Start date
2020-07-28
Completion date
Unknown
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia

Brief summary

Plasma antithrombin (AT) activity levels

Detailed description

Number of participants reported with adverse events, Fitusiran plasma concentrations

Interventions

DRUGSAR439774

Sponsors

Genzyme Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Plasma antithrombin (AT) activity levels—

Secondary

MeasureTime frame
Number of participants reported with adverse events, Fitusiran plasma concentrations—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026